ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in both diseases
Frontline triplet regimen including PVEK shows promise for hard-to-treat AML in patients who are not eligible for intensive chemotherapy
PVEK monotherapy demonstrates strong responses, enables stem cell transplant for high-risk subgroup of BPDCN patients
ORLANDO, DECEMBER 8, 2025 – Researchers from The ...